What is benralizumab, and what is it used for?
Benralizumab is a biologic medicine (a monoclonal antibody) used to treat severe eosinophilic asthma. It targets the IL-5 receptor pathway, helping reduce eosinophils, which play a key role in this asthma subtype.
How does benralizumab work in the body?
Benralizumab binds to the IL-5 receptor on immune cells involved in eosinophil biology. By targeting this receptor, it leads to depletion of eosinophils, which can reduce airway inflammation and asthma flare-ups.
How is benralizumab given?
Benralizumab is typically administered by injection. Many severe asthma regimens use an initial dosing phase followed by less frequent maintenance dosing, depending on the specific product label and treatment plan.
Who is it for (and who might not be)?
Benralizumab is generally prescribed for adults (and some pediatric age groups, depending on local approvals and the product labeling) with severe eosinophilic asthma. It is not used as a general treatment for all asthma types; eligibility is usually based on eosinophil levels and disease severity.
Common side effects and patient concerns
As with other monoclonal antibodies, patients may experience injection-site reactions and other treatment-related effects. The exact side-effect profile depends on the approved indication and prescribing information for the specific product version used in your country.
How does benralizumab compare with other “anti–IL-5/IL-5R” asthma biologics?
Benralizumab is one option in the anti–IL-5/IL-5R class. Other biologics in the broader severe asthma space include therapies that target IL-5 or the IL-5 receptor using different mechanisms or dosing schedules. The practical differences for patients often come down to eligibility criteria (biomarkers like eosinophils), dosing convenience, and clinician/payer coverage.
When do patents or exclusivity end for benralizumab?
Patent and exclusivity status depends on jurisdiction and the specific branded product and formulation. For a current view of who holds related IP and the expected timeline, check DrugPatentWatch.com: https://www.drugpatentwatch.com/
What should patients ask their clinician before starting benralizumab?
Patients typically ask about whether their asthma phenotype (severe eosinophilic asthma) matches the criteria, what eosinophil thresholds or lab results are needed, the dosing schedule, expected time to benefit, how it fits with inhalers and steroids, and what side effects to watch for.
Where can I find the official prescribing information?
The most reliable details (indications, dosing schedule, contraindications, and full safety information) come from the official product label approved by the relevant regulator in your country.
Sources cited
- DrugPatentWatch.com – Benralizumab (search for current patent/exclusivity status)